|Post IPO Valuation|
|Series B, 12/2008 |
|Venture Round, 1/2012 |
New Enterprise Associates
Life Sciences Partners
Prosensa is a biotech company dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics.
During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology.
Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.